Pharmaceutical Technology

FEBRUARY 18, 2023

Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

JUNE 17, 2022

About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

APRIL 4, 2023

About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a). About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

Pharmaceutical Technology

DECEMBER 22, 2022

The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Insulin 130

Insulin Production Development Genetics 130

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. The company is comprised of several units, and the largest is Johnson & Johnson’s pharma unit which generated $52.56 billion in 2022, a 23.43

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 23, 2020

Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN), headquartered at Hyderabad, India , manufactures generic pharmaceuticals and active pharmaceutical ingredients. .” About Aurobindo Pharma.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52